Brain fog of post-COVID-19 condition and Chronic Fatigue Syndrome, same medical disorder?
Brain fog
Cognition
Hyposmia
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Neuropsychological impairment
Post-COVID-19 condition
SARS-CoV-2
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
06 12 2022
06 12 2022
Historique:
received:
02
09
2022
accepted:
08
11
2022
entrez:
6
12
2022
pubmed:
7
12
2022
medline:
15
12
2022
Statut:
epublish
Résumé
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is characterized by persistent physical and mental fatigue. The post-COVID-19 condition patients refer physical fatigue and cognitive impairment sequelae. Given the similarity between both conditions, could it be the same pathology with a different precipitating factor? To describe the cognitive impairment, neuropsychiatric symptoms, and general symptomatology in both groups, to find out if it is the same pathology. As well as verify if the affectation of smell is related to cognitive deterioration in patients with post-COVID-19 condition. The sample included 42 ME/CFS and 73 post-COVID-19 condition patients. Fatigue, sleep quality, anxiety and depressive symptoms, the frequency and severity of different symptoms, olfactory function and a wide range of cognitive domains were evaluated. Both syndromes are characterized by excessive physical fatigue, sleep problems and myalgia. Sustained attention and processing speed were impaired in 83.3% and 52.4% of ME/CFS patients while in post-COVID-19 condition were impaired in 56.2% and 41.4% of patients, respectively. Statistically significant differences were found in sustained attention and visuospatial ability, being the ME/CFS group who presented the worst performance. Physical problems and mood issues were the main variables correlating with cognitive performance in post-COVID-19 patients, while in ME/CFS it was anxiety symptoms and physical fatigue. The symptomatology and cognitive patterns were similar in both groups, with greater impairment in ME/CFS. This disease is characterized by greater physical and neuropsychiatric problems compared to post-COVID-19 condition. Likewise, we also propose the relevance of prolonged hyposmia as a possible marker of cognitive deterioration in patients with post-COVID-19.
Sections du résumé
BACKGROUND
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is characterized by persistent physical and mental fatigue. The post-COVID-19 condition patients refer physical fatigue and cognitive impairment sequelae. Given the similarity between both conditions, could it be the same pathology with a different precipitating factor?
OBJECTIVE
To describe the cognitive impairment, neuropsychiatric symptoms, and general symptomatology in both groups, to find out if it is the same pathology. As well as verify if the affectation of smell is related to cognitive deterioration in patients with post-COVID-19 condition.
METHODS
The sample included 42 ME/CFS and 73 post-COVID-19 condition patients. Fatigue, sleep quality, anxiety and depressive symptoms, the frequency and severity of different symptoms, olfactory function and a wide range of cognitive domains were evaluated.
RESULTS
Both syndromes are characterized by excessive physical fatigue, sleep problems and myalgia. Sustained attention and processing speed were impaired in 83.3% and 52.4% of ME/CFS patients while in post-COVID-19 condition were impaired in 56.2% and 41.4% of patients, respectively. Statistically significant differences were found in sustained attention and visuospatial ability, being the ME/CFS group who presented the worst performance. Physical problems and mood issues were the main variables correlating with cognitive performance in post-COVID-19 patients, while in ME/CFS it was anxiety symptoms and physical fatigue.
CONCLUSIONS
The symptomatology and cognitive patterns were similar in both groups, with greater impairment in ME/CFS. This disease is characterized by greater physical and neuropsychiatric problems compared to post-COVID-19 condition. Likewise, we also propose the relevance of prolonged hyposmia as a possible marker of cognitive deterioration in patients with post-COVID-19.
Identifiants
pubmed: 36474290
doi: 10.1186/s12967-022-03764-2
pii: 10.1186/s12967-022-03764-2
pmc: PMC9724286
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
569Informations de copyright
© 2022. The Author(s).
Références
Lancet Infect Dis. 2022 Jan;22(1):43-55
pubmed: 34480857
Nature. 2022 Apr;604(7907):697-707
pubmed: 35255491
Neuropsychol Rev. 2000 Sep;10(3):131-49
pubmed: 10983898
BMJ. 2020 Dec 23;371:m4938
pubmed: 33361141
J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1308-1319
pubmed: 29735513
Am J Public Health. 1997 Sep;87(9):1449-55
pubmed: 9314795
J Intern Med. 2011 Oct;270(4):327-38
pubmed: 21777306
J Community Psychol. 2018 Nov;46(8):959-971
pubmed: 30311972
Rev Bras Anestesiol. 2011 Sep-Oct;61(5):641-58, 351-60
pubmed: 21920214
Med Clin (Barc). 2011 Mar 12;136(6):239-43
pubmed: 21145567
J Sports Sci. 2012 May;30(9):841-50
pubmed: 22494399
Diagnostics (Basel). 2019 Aug 07;9(3):
pubmed: 31394725
Healthcare (Basel). 2021 May 25;9(6):
pubmed: 34070367
J Neurosci. 2009 Nov 4;29(44):13746-50
pubmed: 19889986
J Health Psychol. 2020 Nov-Dec;25(13-14):2106-2117
pubmed: 29992837
Curr Psychiatry Rep. 2013 Apr;15(4):353
pubmed: 23440559
J Neuroimaging. 2020 Nov;30(6):822-827
pubmed: 32609410
Int J Environ Res Public Health. 2022 Feb 06;19(3):
pubmed: 35162857
Eur J Intern Med. 2021 Oct;92:55-70
pubmed: 34167876
Psychol Aging. 2014 Sep;29(3):658-65
pubmed: 25244484
Front Physiol. 2017 Feb 17;8:88
pubmed: 28261110
Dement Geriatr Cogn Disord. 2021;50(1):68-73
pubmed: 33853062
Lancet Infect Dis. 2022 Apr;22(4):e102-e107
pubmed: 34951953
Ann Intern Med. 1994 Dec 15;121(12):953-9
pubmed: 7978722
Front Physiol. 2013 Apr 05;4:63
pubmed: 23576989
J Transl Med. 2021 Dec 4;19(1):494
pubmed: 34863209
Behav Brain Funct. 2011 Oct 27;7:46
pubmed: 22032726
Lancet Neurol. 2014 Oct;13(10):1017-28
pubmed: 25231524
J Neurovirol. 2021 Aug;27(4):631-637
pubmed: 34341960
Immunol Res. 2021 Apr;69(2):205-211
pubmed: 33786700
J Clin Med. 2020 Aug 05;9(8):
pubmed: 32764516
Front Pediatr. 2019 Feb 05;7:12
pubmed: 30805319
Trends Mol Med. 2021 Sep;27(9):895-906
pubmed: 34175230
Psychosom Med. 2009 Jun;71(5):557-65
pubmed: 19414619
Front Psychiatry. 2018 Nov 16;9:589
pubmed: 30505285
Microorganisms. 2021 Aug 12;9(8):
pubmed: 34442798
Anesth Analg. 2007 May;104(5):1223-9, tables of contents
pubmed: 17456678
Front Psychiatry. 2021 Oct 11;12:735784
pubmed: 34707521
Appl Neuropsychol Adult. 2014;21(2):120-7
pubmed: 24826505